Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) [Internet]. 2014 Sep. 4 [cited 2026 Apr. 16];12(3):438. Available from: https://pharmacypractice.org/index.php/pp/article/view/438